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ABSTRACT
Objective: To assess the effect of inducing covariation among
simulated high-density lipoprotein (HDL-C), triglyceride,
and total cholesterol values on Framingham risk equation
results.
Methods: National Health and Nutrition Examination
Survey (NHANES) data were used to estimate means and
standard deviations for HDL-C, triglyceride, and total cho-
lesterol for all Type II diabetic patients (N = 293) and
patients with metabolic syndrome (N = 2303). NHANES
data were also used to estimate correlations between HDL-
C, triglyceride, and total cholesterol. Data were simulated
and bootstrapped for 1000 replications of the numbers of
patients in NHANES. Four-year risks of coronary heart
disease were estimated using the Framingham risk equation
that includes a nonlinear Weibull function. The differences in
means, with and without correlation, were compared to zero
to determine whether not inducing correlation was associated
with bias. The ratios of variances with and without correla-
tion were compared to one to determine whether not
inducing correlation was associated with a different level of
precision. All simulation results were compared with boot-
strapping results.
Results: Bootstrapping maintained the correlation in the
original data. Inducing correlation leads to more precise
estimates that are closer to the bootstrapped estimates for
Framingham equations not including triglycerides. Using the
Framingham equation for women with triglycerides, the cor-
related simulation data produce less precise estimates than
the uncorrelated data; the uncorrelated data are more precise
than the bootstrapped results.
Conclusion: Not inducing correlation can affect results that
combine multiple simulated parameters using nonlinear func-
tions. Researchers engaged in modeling should consider the
value of inducing correlation in their simulated data.
Keywords: simulation modeling, correlation, risk equations,
lipids.
Introduction
Monte Carlo simulations are often used to explore the
expected effects of pharmaceutical or surgical treat-
ments in a population. Analysts rely on a variety of
recommendations on how to perform these analyses
ranging from recommendations made by a panel con-
vened by the U.S. Department of Health and Human
Services, to the Academy of Managed Care Pharmacy,
to the World Health Organization [1–3]. Additionally,
a range of international recommendations have been
issued over time [4]. Although many of these recom-
mendations comment on simulations as a general
topic, few of them make very speciﬁc recommenda-
tions about simulations. Other introductions to
cost-effectiveness also describe simulations but provide
few details about generating data for Monte Carlo
simulations other than the need to make sure that the
distributions used for individual variables are chosen
in a scientiﬁcally justiﬁable manner [5].
There is statistical literature on repeated measure-
ments in clinical trials that can be related to the issue of
correlation in different measurements [6,7]. Whether
the issue is repeated measurements of a single con-
struct or measuring multiple constructs, the degree
of correlation can be extremely important as it helps
to determine how much additional information is
provided by additional measurements or additional
parameters that are being measured.
Cost-effectiveness analyses focusing on cholesterol
control that have incorporated Monte Carlo simula-
tions have not generally induced covariation in the
simulated data [8]. Covariation (if induced properly)
should not change the mean and variance of the simu-
lated data but may change the mean and variance of
results that combine elements of the simulated data in
nonlinear ways.
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Methods
Two populations for whom dyslipidemia is critical are
patients with type 2 diabetes and patients with meta-
bolic syndrome. Understanding these populations’ risk
of cardiovascular events is an important component
of many pharmacoeconomic analyses. Using Monte
Carlo approaches to simulate data for these popula-
tions is common and feasible given the availability of
data sources such as the National Health and Nutrition
Examination Survey (NHANES). NHANES data are
useful because they are 1) nationally representative; 2)
can be used to estimate means and standard deviations
of individual cholesterol parameters (i.e., triglycerides,
high-density lipoprotein (HDL-C), and total choles-
terol); 3) can be used to determine the appropriate
distribution type (e.g., log normal) for the parameters;
and 4) can be used to estimate the covariance among
the cholesterol parameters [9,10]. The NHANES data
include cholesterol parameters, the presence of diabe-
tes, and the presence of other factors that could be used
to identify a study subject as having metabolic syn-
drome. In this analysis, the National Cholesterol Edu-
cation Program Adult Treatment Panel III deﬁnition of
metabolic syndrome was used (i.e., waist circumference
rather than body mass index) [11].
Induced Covariation
A standard method of inducing covariance among
simulated parameters is the use of the Cholesky
decomposition of the variance-covariance matrix [12].
The Cholesky decomposition can be thought of as
taking the “square root” of a positive deﬁnite matrix
(A), i.e., A = CTC, where C is the Cholesky decompo-
sition and is an upper triangular matrix. We use bold
to denote vectors. The ﬁrst step in the process of simu-
lating three cholesterol parameters was to generate N
random standard normal numbers for each of three
vectors (using g to denote triglycerides, h for HDL-C,
and t for total cholesterol). The data are then formed
into a matrix L = (gThTtT) that has the dimensions
N ¥ 3. For uncorrelated data, E(LTL) = I. It can be
shown that expected variance–covariance matrix of
LC is equal to A. Using σˆ to denote an estimated
standard deviation or covariance, A is constructed
from NHANES data as
A =
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Thus, the result of multiplying the matrix formed by
three vectors of uncorrelated standard normal random
numbers by C (which is related to A as described
earlier) will give a matrix in which the mean of each
column remains zero but the covariance structure is
the same as the covariance structure of triglycerides,
HDL-C, and total cholesterol in the NHANES data.
Each column is then transformed into the distribu-
tion of a cholesterol parameter from the NHANES
data. We describe the process for triglycerides,
although the process for the other two parameters is
similar. For triglycerides, denote the original vector of
random numbers with a standard normal distribution
as gr and each element is gr. Denote the numbers in the
ﬁrst column of LC as gc. Additional steps follow:
1. Form vector gd such that each gd = F(gc; N (0, σˆ g )),
where F denotes the cumulative density function.
All gd will be in the range between zero and one;
2. Using gmin and gmax to denote the minimum and
maximum triglyceride values observed in the rel-
evant subpopulation in NHANES and m to denote
the mean, form vector gl by scaling gd so that
all elements of gl are in the range between F(gmin;
g(shape = / ˆ ˆμ σg g2 2 , scale = ˆ ˆσ μg g2 )) and F(gmax;
g(shape = ˆ ˆμ σg g2 2 , scale = ˆ ˆσ μg g2 )), with the
gamma distribution being chosen by visual inspec-
tion; and;
3. Form vector gs such that for each gs, gl =
F(gs; g(shape = ˆ ˆμ σg g2 2 , scale = σ μg g2 ˆ ).
For HDL-C and total cholesterol, log-normal dis-
tributions were used instead of gamma distributions.
With each set of cholesterol parameters, Framing-
ham risk equations for cardiovascular events at 4 years
were calculated [13]. The risks were calculated for
“lower risk males,” “lower risk females,” “higher risk
males,” and “higher risk females.” The Framingham
risk equations require data inputs for parameters on
age, menopausal status for women, smoking status,
systolic blood pressure, antihypertensive medication,
diabetes, and alcohol consumption. The lower risk
population was assumed to be 40 years old and non-
menopausal (for women). The higher risk population
was assumed to be 60 years old and menopausal (for
women). The lower risk population was assumed to
be nonsmoking while the higher risk population was
assumed to be smokers. The lower risk population
was assumed to have a systolic blood pressure of
140 mm Hg (a ﬁxed value is needed for the Framing-
ham equation) and not be on antihypertensive medi-
cations. In contrast, the higher risk simulation was
assumed to be associated with a systolic blood pressure
of 150 mm Hg and be on antihypertensive medica-
tions. None of the patients with metabolic syndrome
were assumed to be diabetic. In the lower risk simula-
tion, the population was assumed to be nondrinkers
with the opposite being true for the higher risk simu-
lation. The cholesterol parameters were the only part
of the risk equation calculation that varied from one
simulated patient to the next.
For women, two separate risk levels were
calculated—one using triglycerides and one not using
triglycerides. There is evidence that triglycerides are an
independent risk factor, although this is still ques-
940 Frick et al.
tioned in some parts of the literature and the triglyc-
erides do not appear in the risk equation for men [14].
To explore the range of results, the simulation was
repeated 1000 times for each of the diabetic and meta-
bolic syndrome patient populations. The number of
observations in each simulation was the number of
observations in the NHANES data. In each replication,
the order of the three parameters was chosen ran-
domly. As C is an upper triangular matrix, the ﬁrst
column of LC is identical to the ﬁrst column of L.
Thus, if we did not vary the order among replications,
we would trivially have identical results for the ﬁrst
parameter.
Comparing the Results with Induced Covariation with
Other Options
As mentioned, past pharmacoeconomic evaluations
have not generally induced covariation among the
triglycerides, HDL-C, and total cholesterol in dys-
lipidemia interventions. We can isolate the effect of
inducing covariation by repeating all calculations
described earlier, except that in each case, matrix A
will include all zeros as the off-diagonal elements of the
matrix. To test the effect on the Framingham results,
for each gr we calculated the difference between the
means and the ratio of the variances of the Framing-
ham results for each of the six risks calculated when
using As with nonzero and zero covariances. After
ordering the results, we describe the range of the rep-
lications between the 2.5th percentile and 97.5th per-
centile and indicate whether the ranges include zero
(for the mean) and one (for the variances).
We also compare the results with the actual data.
Given the non-normality of the distribution of the
cholesterol parameters and the distribution of the
Framingham results, we used a bootstrap approach to
describe the distribution of the mean and standard
deviation. We repeated the bootstrap 1000 times as
well. Although the NHANES data include information
on parameters other than cholesterol levels, we only
allowed the cholesterol parameters to vary when cal-
culating Framingham risk equations—in other words
we bootstrapped only the cholesterol parameters
themselves.
The software R was used for all analyses.
Results
The means and standard deviations of triglycerides,
HDL-C, and total cholesterol for all patients with type
2 diabetes and all patients with metabolic syndrome
are shown in Table 1. The parameters are similar in the
two clinical populations, except that diabetic patients
have higher triglyceride levels.
The covariances observed in the NHANES data are
shown in the ﬁrst column of data in Table 2. For both
clinical populations, the covariance between triglycer-
ides and HDL-C is negative while the covariance of
each of triglyceride and HDL-C with total cholesterol
is positive. Table 2 also includes results from the 1000
simulations using A with nonzero levels of covariance
and from the 1000 bootstrapping replications. In each
case the covariance estimated from the data is in the
range of the middle 95% of simulations. The median
simulation result is attenuated toward zero in compari-
son with both the value estimated from the data and
the median bootstrapping replication.
Table 3 describes the range of the simulations with
and without induced covariation and the bootstrap-
ping results. In all cases, the middle 95% of the boot-
strapping replications include the means and standard
deviations estimated from the NHANES data. The
middle 95% of the simulated results always include the
means estimated from the NHANES data. For both
Table 1 Cholesterol parameters for all diabetic and metabolic
syndrome patients from NHANES
Triglyceride HDL-C
Total
cholesterol
All diabetic (N = 293) Mean ( μˆ ) 167.0 46.6 198.7
SD (σˆ ) 75.8 12.4 39.8
All metabolic syndrome
(N = 2303)
Mean ( μˆ ) 151.0 46.7 200.5
SD (σˆ ) 73.3 14.1 42.2
NHANES,National Health and Nutrition Examination Survey; SD, standard deviation.
Table 2 Cholesterol parameter covariance in NHANES data, in 1000 simulations, and in 1000 bootstrapping replications for all
patients and when no cholesterol parameters are in recommended ranges
Covariance in data
Simulations
Cov. (Quantiles)
Bootstrapping
Cov. (Quantiles)
2.5 50 97.5 2.5 50 97.5
All diabetics (N = 293)
TG-HDL -356.6 -419.9 -313.4 -313.8 -461.4 -353.2 -249.6
TG-TC 832.8 426.8 728.9 1056.0 503.1 821.2 1135.4
HDL-TC 108.7 48.6 102.6 160.34 55.7 108.6 166.5
All metabolic syndrome (N = 2303)
TG-HDL -216.3 -230.4 -194.0 -157.6 -258.9 -216.3 -177.7
TG-TC 1179.3 953.4 1087.8 1223.6 1046.0 1175.7 1303.1
HDL-TC 177.3 147.2 172.7 200.7 151.1 176.8 205.9
TG, triglyceride;TC, total cholesterol.
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clinical populations, the triglyceride variation is sufﬁ-
ciently attenuated toward zero that the standard devia-
tion estimated from the NHANES data is not included
in the middle 95% of simulations, but the standard
deviations for HDL-C and total cholesterol are
included in the middle 95% of simulations.
The data in Table 4 describe the results of the
Framingham calculations. For both low-risk men and
low-risk women without triglycerides included in the
calculation, the results with induced covariation are
more similar to the bootstrapped results. This is par-
ticularly notable when comparing the average mean
and average standard deviations. In all cases, the simu-
lation with induced covariance overestimates both
the risk and the variation in the risk by less than the
simulation with no induced covariance. Even at two or
three per thousand, this will make a different once costs
are added. The same is true in the high-risk groups. For
the calculations for low-risk women including triglyc-
erides in the risk equation, the results are more mixed.
The average mean risk and average variation in the risk
is higher with induced covariation. The relationship
between the average mean risk in the simulations and
the average mean risk bootstrapped results is mixed.
The average standard deviation for the data without
induced covariation is less than the average boot-
strapped result. The opposite is true with induced cova-
riation. For the high-risk women, the simulated results
underestimate the risk, although the difference between
the averagemean simulated result and the averagemean
bootstrapped result is less with induced covariation.
For both patients with Type II diabetes and patients
with metabolic syndrome, the standard deviations are
higher in the simulation, with less of an overestimate
when covariation is not induced.
Figure 1 shows the differences between the means
for the Framingham risk equations in the middle 95%
of the simulations. Among patients with type 2 diabe-
tes, there does not appear to be a bias. In contrast,
among metabolic patients, when the Framingham risk
equation that does not include triglycerides is used,
the middle 95% of the simulations are less than zero,
suggesting that using simulation results without
induced covariance would bias the result upward.
Figure 2 shows the ratio of the variances. For both
high- and low-risk for both patients with Type II
diabetes and patients with metabolic syndrome, the
results are consistent. When triglycerides are not
included in the risk equation, simulating data without
inducing covariation would lead to an overestimate of
the variance. In contrast, when including the triglycer-
ides, there is a consistently lower variation in the
Framingham results when covariation is not induced.
Discussion
The results of this study demonstrate the importance
of recognizing that when simulations involve multiple
parameters, investigators should be aware of any
nonzero expected covariation in the multiple param-
eters and consider its potential effect. Essentially,
including covariation is like including a parameter that
would otherwise be missing in the simulation.
Analysts could reasonably ask how much effort
should bemade to induce covariation. This study focus-
ing on cholesterol parameters is instructive because
there is a natural covariation in the values of different
cholesterol parameters as they mutually depend on a
combination of genetics, diet, and activity levels even
before any pharmaceutical intervention occurs.
A critical result is that combining cholesterol param-
eters nonlinearly does not always result in bias when
covariation is not induced. The Framingham risk equa-
tions for patients with Type II diabetes make this clear.
This result is likely due to the large role of diabetes in the
risk equation mitigating the effect of the cholesterol
parameters. In contrast, the Framingham risk equations
Table 3 Quantiles of 1000 replications of simulating or bootstrapping patients’ cholesterol parameters
TG quantiles HDL-C quantiles TC quantiles
2.5 50 97.5 2.5 50 97.5 2.5 50 97.5
All diabetics (N = 293)
Uncorrelated μˆ 157.7 165.8 174.3 44.7 46.1 47.5 193.1 197.5 202.1
σˆ 64.3 69.9 75.2 11.2 12.4 13.6 35.1 38.5 41.3
Correlated μˆ 157.7 165.8 174.3 44.7 46.1 47.5 193.2 197.5 202.3
σˆ 63.9 70.0 75.4 11.2 12.4 13.6 35.3 38.4 41.4
Bootstrapped μˆ 158.9 166.7 175.6 45.2 46.6 48.1 194.3 198.7 203.5
σˆ 69.3 75.5 81.4 10.9 12.4 14.0 36.0 39.6 43.1
All metabolic syndrome (N = 2303)
Uncorrelated μˆ 147.0 149.8 152.5 45.7 46.2 46.8 198.4 200.0 201.8
σˆ 67.0 69.1 71.3 13.5 14.1 14.6 40.8 42.2 43.6
Correlated μˆ 146.9 149.9 152.5 45.7 46.2 46.8 198.4 200.0 201.7
σˆ 66.9 69.1 71.3 13.5 14.1 14.6 40.8 42.2 43.6
Bootstrapped μˆ 147.9 151.1 154.0 46.2 46.7 47.3 198.9 200.6 202.2
σˆ 71.1 73.3 75.6 13.5 14.1 14.7 40.7 42.2 43.8
TG, triglyceride;TC, total cholesterol.
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for patients with metabolic syndrome but without dia-
betes demonstrate the importance of inducing covaria-
tion for avoiding bias. As a result of these mixed
ﬁndings, an analyst interested only in a point estimate of
the cost-effectiveness of an interventionmay not need to
induce covariation to avoid biasing the result. This
would even be true for an extended univariate sensitiv-
ity analysis approach like tornado diagrams.
Nevertheless, for analysts running multiple simula-
tions to indicate the precision of the estimates coming
from a decision analysis, a failure to induce covaria-
tion can be critical. The results show that the differ-
ence clearly depends on the exact equation that is
being estimated from the simulated data and the type
of correlation that is induced. In most cases in this
study, precision is increased when allowing correla-
tion, but when the female Framingham risk equation
with triglycerides was examined, inducing correlation
actually made the risk results less precise. The reasons
for the differences in simulations with and without
induced covariation are clear. With induced positive
covariation between HDL-C and total cholesterol, this
will compress the range of their ratio which appears in
the male Framingham equation and in the female
equation without triglycerides. Nevertheless, given a
negative covariation between each of total cholesterol
and HDL-C and triglycerides and an effect of triglyc-
erides in the risk equation that is opposite that of the
ratio between total cholesterol and HDL-C, this
would tend to widen the variation in the Framingham
risk equation. This analysis demonstrates that the
covariation is strong enough in observed data to be
worth considering.
An analyst trying to determine the best course of
action when using the equations with triglycerides
would face a trade-off between using results that more
Table 4 Framingham risk quantiles from 1000 replications of simulating or bootstrapping patients cholesterol parameters
All diabetics
(N = 293 in each replication)
All metabolic syndrome
(N = 2303 in each replication)
2.5 50 97.5 Mean 2.5 50 97.5 Mean
Low-risk male
Uncorrelated μˆ 0.024 0.025 0.026 0.02484 0.014 0.015 0.015 0.01472
σˆ 0.009 0.010 0.011 0.01015 0.006 0.007 0.007 0.00682
Correlated μˆ 0.023 0.024 0.025 0.02444 0.014 0.014 0.015 0.01432
σˆ 0.008 0.009 0.010 0.00885 0.005 0.006 0.006 0.00556
Bootstrapped μˆ 0.023 0.024 0.025 0.02412 0.014 0.014 0.014 0.01401
σˆ 0.008 0.008 0.009 0.00845 0.005 0.005 0.005 0.00513
Low-risk female—No TG
Uncorrelated μˆ 0.018 0.018 0.019 0.01836 0.009 0.009 0.009 0.00878
σˆ 0.007 0.007 0.008 0.00748 0.004 0.004 0.004 0.00406
Correlated μˆ 0.017 0.018 0.019 0.01807 0.008 0.009 0.009 0.00855
σˆ 0.006 0.007 0.007 0.00652 0.003 0.003 0.003 0.00331
Bootstrapped μˆ 0.018 0.018 0.019 0.01784 0.008 0.008 0.008 0.00836
σˆ 0.005 0.006 0.007 0.00622 0.003 0.003 0.003 0.00305
Low-risk female—with TG
Uncorrelated μˆ 0.014 0.014 0.015 0.01410 0.007 0.007 0.007 0.00689
σˆ 0.004 0.005 0.005 0.00451 0.002 0.002 0.003 0.00247
Correlated μˆ 0.014 0.014 0.015 0.01428 0.007 0.007 0.007 0.00693
σˆ 0.005 0.005 0.006 0.00505 0.003 0.003 0.003 0.00260
Bootstrapped μˆ 0.014 0.014 0.015 0.01417 0.007 0.007 0.007 0.00686
σˆ 0.005 0.005 0.005 0.00502 0.002 0.003 0.003 0.00255
High-risk male
Uncorrelated μˆ 0.215 0.223 0.232 0.22329 0.137 0.139 0.141 0.13900
σˆ 0.070 0.078 0.086 0.07845 0.056 0.058 0.061 0.05844
Correlated μˆ 0.213 0.221 0.228 0.22091 0.134 0.136 0.138 0.13609
σˆ 0.063 0.069 0.076 0.06932 0.047 0.048 0.050 0.04845
Bootstrapped μˆ 0.211 0.219 0.226 0.21861 0.131 0.133 0.135 0.13345
σˆ 0.061 0.067 0.073 0.06684 0.043 0.045 0.047 0.04502
High-risk female—no TG
Uncorrelated μˆ 0.124 0.129 0.134 0.12905 0.063 0.064 0.065 0.06388
σˆ 0.043 0.048 0.054 0.04854 0.027 0.028 0.030 0.02830
Correlated μˆ 0.122 0.127 0.132 0.12735 0.061 0.062 0.063 0.06233
σˆ 0.038 0.043 0.047 0.04262 0.022 0.023 0.024 0.02325
Bootstrapped μˆ 0.121 0.126 0.130 0.12590 0.060 0.061 0.062 0.06105
σˆ 0.037 0.041 0.045 0.04092 0.020 0.021 0.022 0.02150
High-risk female—with TG
Uncorrelated μˆ 0.601 0.615 0.626 0.61486 0.373 0.377 0.381 0.37690
σˆ 0.103 0.111 0.119 0.11143 0.098 0.101 0.104 0.10104
Correlated μˆ 0.601 0.615 0.628 0.61492 0.374 0.378 0.382 0.37800
σˆ 0.114 0.123 0.132 0.12329 0.103 0.106 0.109 0.10646
Bootstrapped μˆ 0.633 0.644 0.656 0.64450 0.408 0.411 0.415 0.41140
σˆ 0.093 0.100 0.107 0.09989 0.086 0.089 0.091 0.08864
TG, triglyceride;TC, total cholesterol.
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closely replicate the means of the bootstrapping repli-
cations but have a higher overestimate of the variation
and using results that more closely replicate the vari-
ance of the bootstrapping replications but have a
greater difference with the average. It would seem rea-
sonable to choose to more closely replicate the average
of the bootstrapping replications and allow for a larger
variation to conservatively describe the precision of the
results.
At present, simulations are used in ﬁnal decision
analyses that can be used in the process of making
policy recommendations or developing treatment
guidelines. Failure to account for correlation that led
to a more precise estimate of the outcome would make
it more difﬁcult to conclude there was a signiﬁcant
impact and would create an even greater bias toward
conservative conclusions and policy decisions than
already exists because of statistical testing. Further,
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Figure 1 Range of differences in mean 4-year risk derived from applying the Framingham equation to correlated and uncorrelated simulation data for
all patients (spanning 2.5th percentile to 97.5th percentile).TG, triglyceride;TC, total cholesterol.
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failure to account for correlation in simulation-based
study design would lead to a misestimate of the sample
size necessary to achieve a given level of power.
Although the possibility of using induced correla-
tion to achieve more precise estimates is appealing, it is
equally important when less precise results emerge
after inducing correlation, as with the women with
metabolic syndrome when including triglycerides. The
key is not necessarily achieving a study with more
precision; the key is to achieve a study with the correct
level of precision.
The analyses in this article demonstrate only one
correlation matrix applied to one set of parameters. At
moderate levels of correlation, the correlation affects
results. This research does not indicate what minimum
level of correlation is necessary for inducing correla-
tion to make a difference. Future research using other
populations or other clinical parameters that are cor-
related and related risk equations will need to be
explored to establish just how little correlation is nec-
essary to make a difference.
In conclusion, the analyses in this article demon-
strate that the failure to account for correlation can
lead to a misestimate of the precision of the simulated
result although it does not lead to bias. Analysts using
models to obtain a single point estimate of any risk
function will not necessarily need to concern them-
selves with the multiple variable correlations in simu-
lations. Nevertheless, any use of multiple replications
to obtain an estimate of the precision of a decision
analysis result or to aid in study design may be misin-
formed. A key beneﬁt is being better able to distinguish
between the effects of alternative simulated interven-
tions in pharmacoeconomic evaluations. If, instead,
results are less precise after correlation, it will be more
difﬁcult to conclude that there is a signiﬁcant differ-
ence, but any conclusion that is drawn will be more
statistically appropriate.
We would like to thank Robert Simko and Russell Burge for
their helpful comments on the article.
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